Testosterone Cypionate

Summary

Testosterone Cypionate (CHEMBL1201101) is an approved small molecule; indicated across 9 conditions including hypogonadism and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 9 conditions
• Clinical trials: 33
• Chemistry: 412.6 Da · C27H40O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201101
Name	Testosterone Cypionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	441404
ChEBI	CHEBI:9463
Molecular formula	C27H40O3
Molecular weight	412.6
InChIKey	HPFVBGJFAYZEBE-ZLQWOROUSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=CC(=O)CC[C@]35C

IUPAC name: [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate

Also known as: Azmiro, Andro-cyp, Depo-testosterone, Depotest, NSC-9157, Testosterone cipionate, Testosterone cypionate, Testosterone cypionate ciii, TESTOSTERONE CYPIONATE

Patent coverage: 3,835 distinct patent families (9,823 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypogonadism	4	MONDO:0002146	MONDO:0002146
neoplasm	4	MONDO:0005070	EFO:0000616
orchitis	4	MONDO:0006882	EFO:1001078
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196
diabetic neuropathy	2	MONDO:0006626	EFO:1000783
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
prostate carcinoma	2	MONDO:0005159	EFO:0001663
physiological sexual disorder	1	MONDO:0002134	EFO:0004714

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 33.

Phase distribution

Phase	Trials
PHASE2	17
PHASE4	7
PHASE1	4
Not specified	3
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06592144	PHASE4	ACTIVE_NOT_RECRUITING	TESTO-TRIAL: Use of Testosterone in Critically Ill Patients
NCT07092527	PHASE4	RECRUITING	Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
NCT07278362	PHASE4	NOT_YET_RECRUITING	Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
NCT02408445	PHASE4	COMPLETED	Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment
NCT03325647	PHASE4	COMPLETED	TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY
NCT04439799	PHASE4	COMPLETED	A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
NCT06450405	PHASE4	TERMINATED	Androgen Effects on the Reproductive Neuroendocrine Axis
NCT03038919	PHASE2/PHASE3	UNKNOWN	Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness
NCT04345666	PHASE2/PHASE3	WITHDRAWN	Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair
NCT04363164	PHASE2	RECRUITING	Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04558866	PHASE2	ACTIVE_NOT_RECRUITING	Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
NCT06039371	PHASE2	RECRUITING	Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT06059118	PHASE2	RECRUITING	Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06100705	PHASE2	RECRUITING	Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
NCT06111209	PHASE2	RECRUITING	The Anabolic Effect of Testosterone on Pelvic Floor Muscles
NCT06922318	PHASE2	RECRUITING	The COSMYC Trial (COmbined Suppression of MYC)
NCT07142551	PHASE2	RECRUITING	Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
NCT00853502	PHASE2	WITHDRAWN	The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa
NCT01750398	PHASE2	COMPLETED	Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
NCT02090114	PHASE2	COMPLETED	RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT02286921	PHASE2	COMPLETED	Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
NCT03516812	PHASE2	COMPLETED	Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
NCT03554317	PHASE2	COMPLETED	COMbination of Bipolar Androgen Therapy and Nivolumab
NCT03716739	PHASE2	COMPLETED	Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT04424654	PHASE2	COMPLETED	Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy
NCT04895306	PHASE2	COMPLETED	Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
NCT04731376	PHASE1	ACTIVE_NOT_RECRUITING	Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
NCT06305598	PHASE1	RECRUITING	Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT01378299	PHASE1	COMPLETED	CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
NCT02995330	PHASE1	TERMINATED	Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
NCT07568574	Not specified	ENROLLING_BY_INVITATION	Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes
NCT04551144	Not specified	TERMINATED	Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors
NCT05487794	Not specified	COMPLETED	Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).